Assessing the impact of insulin glargine and detemir treatment to serum total IGF1 levels in the insulin-naive type 2 diabetic patients
dc.contributor.author | Dizdar, Oğuzhan Sıtkı | |
dc.contributor.author | Koca, Nizameddin | |
dc.contributor.author | Aydın, Taner | |
dc.contributor.buuauthor | Cander, Soner | |
dc.contributor.buuauthor | Gül, Özen Öz | |
dc.contributor.buuauthor | Sarandöl, Emre | |
dc.contributor.buuauthor | Ersoy, Canan | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Endokrinoloji ve Metabolizma Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Biyokimya Anabilim Dalı. | tr_TR |
dc.contributor.orcid | 0000-0002-2593-7196 | tr_TR |
dc.contributor.researcherid | AAI-1005-2021 | tr_TR |
dc.contributor.researcherid | ABE-1716-2020 | tr_TR |
dc.contributor.researcherid | AAH-8861-2021 | tr_TR |
dc.contributor.scopusid | 25027068600 | tr_TR |
dc.contributor.scopusid | 26040787100 | tr_TR |
dc.contributor.scopusid | 55943324800 | tr_TR |
dc.contributor.scopusid | 6701485882 | tr_TR |
dc.date.accessioned | 2023-03-02T12:33:32Z | |
dc.date.available | 2023-03-02T12:33:32Z | |
dc.date.issued | 2017-06 | |
dc.description.abstract | Aim: The mitogenic potential of analog insulins due to their different insulin-like growth factor-1 (IGF1) receptor affinity is a situation that causes concern related to cancer risk. We aimed to examine the changes in the serum IGF1 levels formed by insulin glargine and detemir in the insulin-naive type 2 diabetic patients. Methods: The serum total IGF1 levels of the 62 insulin-naive type 2 diabetic patients were studied before and after 12 weeks of the started treatment with basal insulin analogs. Twenty-two and twenty patients (Group I and II) using the single-dose and double-dose insulin detemir and twenty patients (Group III) using insulin glargine were evaluated. Results: In Group I and Group II, the average 8.5% and 0.1% increases and in the Group III, 6.5% decreases were determined in the IGF1 values. The IGF1 changes were significant in the men but not in the women. Conclusion: In our study, it was determined that the insulin glargine depressed the serum IGF1 levels much more when compared to the insulin detemir. This result can be evaluated as the in vivo reflection of the in vitro findings related to the fact that the IGF1 receptor affinity of the glargine is higher. | en_US |
dc.identifier.citation | Cander, S. vd. (2017). ''Assessing the impact of insulin glargine and detemir treatment to serum total IGF1 levels in the insulin-naive type 2 diabetic patients''. Metabolic Syndrome and Related Disorders, 15(5), 220-225. | en_US |
dc.identifier.endpage | 225 | tr_TR |
dc.identifier.issn | 1540-4196 | |
dc.identifier.issn | 1557-8518 | |
dc.identifier.issue | 5 | tr_TR |
dc.identifier.pubmed | 28394183 | tr_TR |
dc.identifier.scopus | 2-s2.0-85019883899 | tr_TR |
dc.identifier.startpage | 220 | tr_TR |
dc.identifier.uri | https://doi.org/10.1089/met.2017.0005 | |
dc.identifier.uri | https://www.liebertpub.com/doi/10.1089/met.2017.0005 | |
dc.identifier.uri | http://hdl.handle.net/11452/31306 | |
dc.identifier.volume | 15 | tr_TR |
dc.identifier.wos | 000401726400003 | tr_TR |
dc.indexed.pubmed | PubMed | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Mary Ann Liebert | en_US |
dc.relation.collaboration | Sanayi | tr_TR |
dc.relation.journal | Metabolic Syndrome and Related Disorders | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Research & experimental medicine | en_US |
dc.subject | Insulin analogs | en_US |
dc.subject | Detemir | en_US |
dc.subject | Glargine | en_US |
dc.subject | IGF1 | en_US |
dc.subject | Diabetescancer | en_US |
dc.subject | Growth-factor-I | en_US |
dc.subject | Analogs | en_US |
dc.subject | Cancer | en_US |
dc.subject | Receptor | en_US |
dc.subject | Binding | en_US |
dc.subject | Malignancies | en_US |
dc.subject | Metabolites | en_US |
dc.subject | Population | en_US |
dc.subject | Metformin | en_US |
dc.subject | Therapy | en_US |
dc.subject.emtree | Insulin detemir | en_US |
dc.subject.emtree | Insulin glargine | en_US |
dc.subject.emtree | Antidiabetic agent | en_US |
dc.subject.emtree | Biological marker | en_US |
dc.subject.emtree | Glycosylated hemoglobin | en_US |
dc.subject.emtree | Hemoglobin A1c protein, human | en_US |
dc.subject.emtree | IGF1 protein, human | en_US |
dc.subject.emtree | Insulin detemir | en_US |
dc.subject.emtree | Insulin glargine | en_US |
dc.subject.emtree | Somatomedin C | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.emtree | Aged | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | Diabetic patient | en_US |
dc.subject.emtree | Drug screening | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Follow up | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | In vivo study | en_US |
dc.subject.emtree | Insulin treatment | en_US |
dc.subject.emtree | Major clinical study | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Non insulin dependent diabetes mellitus | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Protein blood level | en_US |
dc.subject.emtree | Single drug dose | en_US |
dc.subject.emtree | Treatment duration | en_US |
dc.subject.emtree | Blood | en_US |
dc.subject.emtree | Comparative study | en_US |
dc.subject.emtree | Down regulation | en_US |
dc.subject.emtree | Drug effects | en_US |
dc.subject.emtree | Glucose blood level | en_US |
dc.subject.emtree | Metabolism | en_US |
dc.subject.emtree | Middle aged | en_US |
dc.subject.emtree | Non insulin dependent diabetes mellitus | en_US |
dc.subject.emtree | Time factor | en_US |
dc.subject.emtree | Treatment outcome | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Aged | en_US |
dc.subject.mesh | Biomarkers | en_US |
dc.subject.mesh | Blood glucose | en_US |
dc.subject.mesh | Diabetes mellitus | en_US |
dc.subject.mesh | Type 2 | en_US |
dc.subject.mesh | Down-regulation | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Glycated hemoglobin A | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Hypoglycemic agents | en_US |
dc.subject.mesh | Insulin detemir | en_US |
dc.subject.mesh | Insulin glargine | en_US |
dc.subject.mesh | Insulin-like growth factor I | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Middle aged | en_US |
dc.subject.mesh | Time factors | en_US |
dc.subject.mesh | Treatment outcome | en_US |
dc.subject.scopus | Diabetes Mellitus; Biguanide Derivative; Cancer Risk | en_US |
dc.subject.wos | Medicine, research & experimental | en_US |
dc.title | Assessing the impact of insulin glargine and detemir treatment to serum total IGF1 levels in the insulin-naive type 2 diabetic patients | en_US |
dc.type | Article | |
dc.wos.quartile | Q3 | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: